SEC Form 4 · accession 0001209191-16-144650
Fulgent Genetics, Inc. · FLGT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hanlin Gao
Officer — Chief Scientific Officer · 10% Owner
Period of report
May 13, 2016
Accepted (ET)
Oct 4, 2016 · 6:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674930
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Predecessor Class D Voting Common UnitsF1 | May 13, 2016 | S | 2,565,789 | $1.1669 | D | 13,434,211 | D | |
| Predecessor Class D Voting Common UnitsF1,F2 | Sep 30, 2016 | D | 13,434,211 | — | D | 0 | D | |
| Issuer Common StockF1,F3 | Sep 30, 2016 | A | 1,767,659 | — | A | 1,767,659 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all of the Predecessor's Class D voting common units were cancelled in exchange for shares of the Issuer's common stock at a ratio of 7.6-for-1.
- F2The securities were disposed of and cancelled in the Reorganization in exchange for 1,767,659 shares of the Issuer's common stock.
- F3The securities were received in the Reorganization in exchange for the cancellation of 13,434,211 Class D voting common units of the Predecessor.